Skip to main content
Clinical Trials/NCT01533610
NCT01533610
Unknown
Phase 2

The Efficacy of Stellate Ganglion Block as PTSD Therapy: A Pilot Study

Southern California Institute for Research and Education1 site in 1 country12 target enrollmentFebruary 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Stress Disorders, Post-Traumatic
Sponsor
Southern California Institute for Research and Education
Enrollment
12
Locations
1
Primary Endpoint
Difference in CAPS score activity
Last Updated
14 years ago

Overview

Brief Summary

RATIONALE: A stellate ganglion nerve block may help relieve symptoms of post-traumatic stress disorder (PTSD).

PURPOSE: This pilot clinical trial is studying the efficacy of a stellate ganglion nerve block in veterans to reduce the symptoms of PTSD in relatively long-standing (Vietnam era) induced or relatively recently induced PTSD (from deployment in Afghanistan or Iraq as part of Operations Enduring Freedom (OEF), Iraqi Freedom (OIF), and New Dawn (OND).

Detailed Description

Objectives: 1. Stellate ganglion blocks will be performed in a small sample (n = 12) of the local patient population that suffers from PTSD in order to replicate other preliminary findings. 2. The parameters that lead to a successful treatment response will be evaluated by comparing and contrasting the results obtained in younger (n=6) OEF/OIF generation veterans versus older (n=6) Vietnam generation veterans. 3. The individual difference variables that might lead to successful treatment responses will be studied by obtaining correlative measures of psychological and psychometric data and responses to standardized tests. Research Design: This is an open label unblinded clinical pilot case series study to determine the efficacy of stellate ganglion blockade for relief of PTSD symptoms in the Long Beach VA healthcare population.

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
February 2013
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Include significant PTSD symptoms with severe hyper-arousal symptoms.
  • Clinician Administered PTSD Scales (CAPS) score, with a total score ≥ 50 needed for enrollment.
  • Hyper-arousal severity identified by a high score on the CAPS D scale and a ≥ 10 beat per minute increase in heart rate during the subject's verbal recollection of a standardized version of their traumatic exposure.

Exclusion Criteria

  • Include psychiatric and medical conditions that would make patients poor candidates for an outpatient procedure.
  • Subjects must be able to be cooperative for the procedure and free of significant medical problems that would pose a constant threat to life.

Outcomes

Primary Outcomes

Difference in CAPS score activity

Time Frame: Baseline and weeks 1, 4, 12 and 26

Secondary Outcomes

  • Biophysical responses(Baseline and weeks 1, 4, 12 and 26)
  • Depression scale(Baseline and weeks 1, 4, 12 and 26)
  • Anxiety scale(Baseline and weeks 1, 4, 12 and 26)
  • Quality of life scale(Baseline and weeks 1, 4, 12 and 26)

Study Sites (1)

Loading locations...

Similar Trials